Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Editorial [Hot Topic: Vasoactive Intestinal Peptide (VIP): Historic Perspective and Future Potential]
Volume: 12 Issue: 4
Author(s): Neil Foster
Affiliation:
Export Options
About this article
Cite this article as:
Foster Neil, Editorial [Hot Topic: Vasoactive Intestinal Peptide (VIP): Historic Perspective and Future Potential], Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (4) . https://dx.doi.org/10.2174/187153012803832521
DOI https://dx.doi.org/10.2174/187153012803832521 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
23
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drugging Cell Cycle Kinases in Cancer Therapy
Current Drug Targets A Review on the Synthetic Approach of Marinopyrroles: A Natural Antitumor Agent from the Ocean
Letters in Organic Chemistry Isolation of a New Sesquiterpene Lactone From Vernonia Zeylanica (L) Less and its Anti-Proliferative Effects in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Involvement of Mast Cells in Angiogenesis and Chronic Inflammation
Current Drug Targets - Inflammation & Allergy Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews Recent Advances in the Therapeutic Perspectives of Nutlin-3
Current Pharmaceutical Design Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Cytotoxic T Cell Reponses Against Immunoglobulin in Malignant and Normal B Cells: Implications for Tumor Immunity and Autoimmunity
Current Pharmaceutical Design C-KIT Signaling in Cancer Treatment
Current Pharmaceutical Design Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design Molecular Mechanisms Responsible for <i>In Vitro</i> Cytotoxic Attributes of <i>Conyza bonariensis</i> Extract against Lymphoblastic Leukaemia Jurkat Cells
Anti-Cancer Agents in Medicinal Chemistry Secondary Metabolites from Cordyceps Species and Their Antitumor Activity Studies
Recent Patents on Biotechnology In Vivo Imaging of Apoptosis in Cancer: Potentials and Drawbacks of Molecular Probes
Current Molecular Imaging (Discontinued) Chemoresistance in High-Grade Gliomas: Relevance of Adenosine Signalling in Stem-Like Cells of Glioblastoma Multiforme
Current Drug Targets Versatile and Valuable Utilization of Amidohydrolase L-glutaminase in Pharma and Food industries: A Review
Current Drug Metabolism One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Use of Single Nucleotide Polymorphism Array Technology to Improve the Identification of Chromosomal Lesions in Leukemia
Current Cancer Drug Targets Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design N-Hydroxyguanidines as Substrates of Nitric Oxide Synthases
Current Topics in Medicinal Chemistry Plant Secondary Metabolites in Cancer Chemotherapy: Where are We?
Current Pharmaceutical Biotechnology